BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34643108)

  • 1. Progression Rates of LR-2 and LR-3 Observations on MRI to Higher LI-RADS Categories in Patients at High Risk of Hepatocellular Carcinoma: A Retrospective Study.
    Ranathunga D; Osman H; Islam N; McInnes MDF; Munir J; van der Pol CB; Elfaal M; Walsh C
    AJR Am J Roentgenol; 2022 Mar; 218(3):462-470. PubMed ID: 34643108
    [No Abstract]   [Full Text] [Related]  

  • 2. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 4. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.
    Li L; Zheng W; Wang J; Han J; Guo Z; Hu Y; Li X; Zhou J
    AJR Am J Roentgenol; 2022 Sep; 219(3):434-443. PubMed ID: 35441534
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound.
    Tse JR; Shen L; Bird KN; Yoon L; Kamaya A
    AJR Am J Roentgenol; 2022 Nov; 219(5):774-783. PubMed ID: 35703411
    [No Abstract]   [Full Text] [Related]  

  • 10. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 11. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.
    Bae JS; Lee DH; Lee SM; Suh KS; Lee KW; Yi NJ; Lee KB; Kim H; Han JK
    AJR Am J Roentgenol; 2022 Jul; 219(1):86-96. PubMed ID: 35138137
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma.
    Shahbazian H; Birnbaum J; Burns PJ; Shabanan SH; Kanmaniraja D; Reinus J; Kamel I; Sirlin CB; Chernyak V
    Abdom Radiol (NY); 2023 Dec; 48(12):3696-3702. PubMed ID: 37725110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT.
    Hong CW; Chernyak V; Choi JY; Lee S; Potu C; Delgado T; Wolfson T; Gamst A; Birnbaum J; Kampalath R; Lall C; Lee JT; Owen JW; Aguirre DA; Mendiratta-Lala M; Davenport MS; Masch W; Roudenko A; Lewis SC; Kierans AS; Hecht EM; Bashir MR; Brancatelli G; Douek ML; Ohliger MA; Tang A; Cerny M; Fung A; Costa EA; Corwin MT; McGahan JP; Kalb B; Elsayes KM; Surabhi VR; Blair K; Marks RM; Horvat N; Best S; Ash R; Ganesan K; Kagay CR; Kambadakone A; Wang J; Cruite I; Bijan B; Goodwin M; Moura Cunha G; Tamayo-Murillo D; Fowler KJ; Sirlin CB
    Radiology; 2023 Jun; 307(5):e222855. PubMed ID: 37367445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations.
    Sevco TJ; Masch WR; Maturen KE; Mendiratta-Lala M; Wasnik AP; Millet JD
    AJR Am J Roentgenol; 2021 Sep; 217(3):644-650. PubMed ID: 34259543
    [No Abstract]   [Full Text] [Related]  

  • 15. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
    Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
    J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
    Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
    AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence and clinical significance of discordant LI-RADS
    Yokoo T; Singal AG; Diaz de Leon A; Ananthakrishnan L; Fetzer DT; Pedrosa I; Khatri G
    Abdom Radiol (NY); 2020 Jan; 45(1):177-187. PubMed ID: 31342103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
    Chen J; Kuang S; Zhang Y; Tang W; Xie S; Zhang L; Rong D; He B; Deng Y; Xiao Y; Shi W; Fowler K; Wang J; Sirlin CB
    Abdom Radiol (NY); 2021 Apr; 46(4):1530-1542. PubMed ID: 33040166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.